Eon Laboratories

Eon Laboratories was a prominent American generic pharmaceutical company that specialized in the development and manufacture of a wide array of multi-source prescription drugs. Headquartered in Lake Success, New York, the company focused on complex generic formulations across therapeutic areas including cardiovascular health, central nervous system disorders, and infectious diseases. Eon was particularly noted for its robust pipeline of Abbreviated New Drug Applications (ANDAs) and its high-quality manufacturing facilities. In 2005, the company was acquired by Novartis for approximately $2.6 billion and subsequently merged into Sandoz, Novartis's generic pharmaceuticals division. This acquisition significantly expanded Sandoz's footprint in the United States market, leveraging Eon's strong product portfolio and operational expertise.